This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary NGF Therapeutic Antibody Development
Background of NGF
NGF and its receptors are important research and therapeutic targets, particularly in the treatment of neurodegenerative diseases and chronic pain in companion animals. BioVenic has established a platform for the development of veterinary NGF therapeutic antibodies, encompassing animal immunization, antibody preparation, purification, and characterization. Our comprehensive antibody development services assist in finding solutions to alleviate pain and inflammation symptoms in companion animals.
Background of NGF
| Full Name | Nerve growth factor |
|---|---|
| Aliases | Beta-NGF, HSAN5, NGFB. |
| Target Profile | NGF belongs to the neurotrophin family. It is synthesized in the cortex and hippocampus and retrogradely transported to the cell bodies of basal forebrain cholinergic neurons (BFCNs), triggering processes essential for maintaining normal cellular function and morphology. NGF plays a critical role in the stimulation, survival, and phenotype maintenance of adult BFCNs. Overexpression of NGF is associated with the pathophysiology of various diseases, including neurodegenerative disorders, pain, and inflammation. |
MoA of NGF
NGF functions primarily by binding to specific receptors, including the high-affinity receptor TrkA and the low-affinity receptor p75NTR. The binding of NGF to TrkA triggers three main signaling pathways: Ras/Raf/MAPK, PLC-γ, and PI3-kinase/Akt, leading to a series of intracellular events and expression changes in genes responsible for neuronal survival, growth, and differentiation. Meanwhile, p75NTR is involved in various cellular responses, including apoptosis, neurite outgrowth, and myelination. The binding of NGF to p75NTR activates multiple downstream signals, including Rac, NF-κB, and JNK. Neuronal survival is mediated by the activation of NF-κB, while the activation of the MAPK/JNK pathway promotes apoptosis.
Fig.1 Schematic diagram of NGF signaling pathways in neurons.1
Application in Veterinary Therapeutics
Peripheral and central neuronal plasticity are key mechanisms in the development and maintenance of chronic pain, with NGF being a major determinant of this plasticity. Peripherally, NGF can bind to TrkA on mast cells and other immune cells, triggering the release of inflammatory mediators such as histamine, serotonin, and NGF itself, leading to peripheral sensitization and sensitizing adjacent nociceptive neurons. Therefore, antibodies blocking the NGF/TrkA signaling in canine and feline may have therapeutic potential, offering effective pain relief. Additionally, most canine osteosarcomas express TrkA protein. Blocking NGF/TrkA signaling can induce apoptosis in canine osteosarcoma cell lines. Hence, NGF therapeutic antibodies can significantly alleviate pain in canine bone cancer and slow tumor growth progression.
Veterinary NGF Therapeutic Antibody Development Services
NGF is involved in neuronal growth, survival, and pain signal transmission, making therapeutic strategies targeting NGF potentially valuable for controlling pain in canine and feline. Utilizing our diverse and emerging technology, BioVenic offers veterinary NGF therapeutic antibody development services. Our team assists in developing veterinary therapeutic antibodies that specifically bind to NGF and block NGF/TrkA signaling, aiding in providing safer and more effective treatment solutions for companion animals. We also provide antibody characterization, antibody engineering, and species-specific antibody development services to enhance antibody affinity for specific species and reduce safety issues associated with immunogenicity.
Please click the link below for more information about our veterinary NGF therapeutic antibody development services.
Why Choose Us?
BioVenic offers a one-stop services, covering the entire process from antibody screening to preparation and engineering design, customizing antibody development solutions according to your specific need.
We have established a diverse platform for developing veterinary therapeutic antibodies, offering the choices of technologies including hybridoma, single B-cell sorting, and phage display.
Our team conducts strict quality control throughout the veterinary therapeutic antibody development process, ensuring the high purity and stability of antibody samples, and advancing research.
Levels of NGF are elevated in various pain-related disorders, and the administration of NGF therapeutic antibodies has been shown to provide effective analgesia in companion animals. BioVenic offers veterinary NGF therapeutic antibody development services, covering the complete preparation process, and helping you develop high-affinity veterinary NGF therapeutic antibodies. If you are interested in this area, please contact us now.
References
- Niewiadomska, Grazyna, et al. "The cholinergic system, nerve growth factor and the cytoskeleton." Behavioural brain research 221.2 (2011): 515-526.
- Enomoto, Masataka, et al. "Anti‐nerve growth factor monoclonal antibodies for the control of pain in dogs and cats." Veterinary Record 184.1 (2019): 23-23.